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MD 20910, USA
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The development of a vaccine against malaria is a major
research priority given the burden of disease, death and
economic loss inflicted upon the tropical world by this
parasite. Despite decades of effort, however, a vaccine
remains elusive. The best candidate is a subunit vaccine
termed RTS,S but this provides only partial protection
against clinical disease. This review examines what is
known about protective immunity against pre-erythro-
cytic stage malaria by considering the humoral and T
cell-mediated immune responses that are induced by
attenuated sporozoites and by the RTS,S vaccine. On
the basis of these observations a set of research priori-
ties are defined that are crucial for the development of a
vaccine capable of inducing long-lasting and high-grade
protection against malaria.
The scope of the problem
Malaria is caused by the protozoan genus Plasmodium and
is responsible for 700 000 to 1 000 000 deaths per year in
tropical regions of the world, most severely affecting chil-
dren in sub-Saharan Africa [1]. Naturally acquired immu-
nity to malaria is slow to develop, non-sterilizing and
short-lived in the absence of continuous exposure. The
parasite rapidly develops resistance to anti-malarial drugs
and treatment is often followed by reinfection [2]. Hence,
there is an urgent need to develop a malaria vaccine.
This task has proven difficult: after decades of effort, the
only candidate vaccine approaching licensure is RTS,S [3],
a virus-like particle, based on the dominant surface protein
[designated the circumsporozoite protein (CS protein)] of
the Plasmodium falciparum (Pf) sporozoite. RTS,S has the
potential to provide a significant health benefit if the
reductions in clinical illness seen in early field trials are
confirmed in the Phase III trial currently underway in nine
countries across sub-Saharan Africa [3]. However, RTS,S
does not appear potent enough to prevent infection
completely in the majority of vaccine recipients, inducing
only partial immunity. To design a vaccine providing life-
long, sterile protection, it will be important to understand
better the interface of the parasite with the human im-
mune system, including its immune-evasion mechanisms.
This objective is especially relevant for the early (pre-
erythrocytic) sporozoite and liver stages of the infection
where the induction of sterilizing immunity would
completely prevent blood stage malaria and thus both
clinical illness and transmission.
This review highlights what is known about the immu-
nological responses to the pre-erythrocytic stages of the
parasite, focusing on two models of protection: immuniza-
tion with attenuated sporozoites and immunization with
the CS protein. It then identifies key research questions to
guide the development of a highly effective pre-erythrocyt-
ic stage vaccine.
The sporozoite
When an infected female Anopheles mosquito bites, it
injects several hundred sporozoites into the cutaneous
tissue. Over the next minutes to hours some of the spor-
ozoites leave the injection site and enter blood vessels
where they are carried rapidly to the liver, while others
remain in the skin or travel to regional lymph nodes or to
the spleen. On reaching the liver, sporozoites cross the
endothelium, in some cases passing through Kupffer cells
(KC), and then traverse several hepatocytes before enter-
ing a terminal hepatocyte via an invagination process,
leading to the formation of a parasitophorous vacuole in
which each sporozoite differentiates into liver stage and
finally blood stage parasites [4–6] (Figure 1). As the spo-
rozoite passes through a hepatocyte it can cause cell
wounding [4] and in some instances necrosis, although
whether or not this constitutes a danger signal for the
immune system is unclear. The liver stage of infection
appears otherwise to be relatively immunologically silent,
possibly due to the minor antigen (Ag) load, the immune-
tolerant nature of the liver, and/or the immune-regulatory
mechanisms initiated during sporozoite passage through
the skin [7].
The attenuated sporozoite human protection model
In 1973 it was demonstrated that humans subjected to
approximately 1000 to 2000 irradiated and Pf sporozoite-
infected mosquito bites, followed by primary challenge
within 10 weeks after immunization, were protected and
the protection lasted for up to 10months against sporozoite
re-challenge [8,9]. This work followed studies where im-
munization of animals with radiation-attenuated sporo-
zoites was similarly highly protective [10,11]. Recently,
immunization of rodents with genetically attenuated spor-
ozoites (GAS) also afforded high-grade (>90%) protection
[12]. Given the powerful immunity induced by attenuated
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Figure 1. The Plasmodium life cycle. (a) Sporozoites enter the liver lobule either via the portal venule or the hepatic artery, and arrest by binding to the sinusoidal cell layer.
The parasites glide along the sinusoid, sometimes moving against the flow of blood, until they encounter a Kupffer cell. After a pause, they slowly pass through the Kupffer
cell and cross the space of Disse beyond it. Once inside the liver parenchyma, the parasites increase their velocity and migrate for many minutes through several
hepatocytes, before they eventually come to rest in a terminal hepatocyte to initiate development (panel reproduced with permission from [5]). (b) An infected female
Anopheles injects up to several hundred sporozoites into the cutaneous tissue while feeding. Some of the sporozoites leave the injection site and enter blood vessels where
they are carried to the liver. Some of the sporozoites invade hepatocytes (panel (a)) where they undergo asexual multiplication (schizogony) and develop into thousands of
merozoites. The merozoites exit the infected hepatocyte in membrane-bound vesicles (merosomes or extrusomes) which, following rupture, enable the merozoites to
rapidly invade red blood cells thereby initiating blood-stage malaria. During the blood stage, formation of gametocytes also occurs and these are ingested by a feeding
mosquito to initiate the next cycle.
Review Trends in Parasitology xxx xxxx, Vol. xxx, No. x
TREPAR-1028; No. of Pages 9
2
sporozoites, much effort has been expended to identify the
underlying protectivemechanisms, including the antigenic
targets.
Radiation-attenuated sporozoites (RAS), as do native
sporozoites, invade hepatocytes and form a parasitophor-
ous vacuole, but their development is arrested at the early
liver stages [13], creating a repository of early liver stage
Ags which could serve to induce and maintain protracted
immunity. The relatively persistent Ag load is one factor
that distinguishes immunization with attenuated sporo-
zoites from exposure to intact sporozoites under natural
conditions. The CS protein and probably other parasite Ags
cross the vacuolar membrane, possibly via a ‘gatekeeper
complex’ [14], to enter the cytoplasm where they undergo
processing and subsequent presentation on the hepatocyte
surface. It has been demonstrated that sporozoite-infected
hepatocytes can process and present Plasmodium berghei
(Pb) CS-protein epitopes to T cells [15], although it is also
possible that sporozoites and liver-stage Ags egress from
the cell to be ingested and processed by dendritic and other
Ag-presenting cells. Likewise, some of the RAS entering
the liver are directly taken up by dendritic cells (DC) for
processing and presentation to T cells. It is probable that
multiple antigens are involved in protection, in as much as
CS protein contributes to but is not required for protection,
because mice tolerized to CS protein can still be protected
by RAS [16].
The RTS,S human protection model
The surface of the sporozoite is densely packed with pro-
tein. Themost prominent is the CS protein which is shed as
the parasite undergoes motility [17] and cell traversal [18].
The Pf CS protein has N and C terminal regions which
flank a central repeat region consisting of 38 to 40 copies of
the B cell epitope NANP, preceded by a minor central
repeat sequence of alternating NVDP and NANP. Several
CD4 and CD8 T cell epitopes have been mapped to the C
terminus of the CS protein, and some of these are universal
epitopes [19–22]. Currently, there are also extensive efforts
to identify additional sporozoite proteins [23–25].
The relatively potent immunogenicity and prominent
location on the sporozoite surface have made the CS pro-
tein a leading candidate Ag for malaria vaccines. Following
the demonstration that CS-protein-based vaccines can
induce protection in animals, the RTS,S vaccine was de-
veloped to extend this protection to humans [3,26]. RTS,S
consists of the central repeat region and the C terminus of
the Pf CS protein fused to the surface Ag of hepatitis B
virus; this is coexpressed with free surface Ag to form an
hepatitis B surface (HBs) Ag-like particle. RTS,S has been
formulated in different adjuvants including ASO2A, an oil-
in-water emulsion containing QS-21 (a derivative of the
saponin Quil A) and mono-phosphoryl lipid A, and ASO1B,
which is a liposome formulation. The RTS,S vaccine con-
fers sterile immunity to 40–50% of malaria-naı¨ve subjects
against a primary sporozoite challenge, and 40–50% of
subjects protected against the primary challenge are also
protected against rechallenge 5 months later [27]. The Ab-
and cell-mediated immune responses to RTS,S have been
characterized extensively in both protected and non-pro-
tected human volunteers [27,28].
Ab-mediated immunity
There is evidence that humoral immunity contributes to
protection against pre-erythrocytic stage malaria. Passive
transfer of monoclonal Ab specific for the central repeat
regions of Pb and P. yoelii (Py) CS protein protects mice
against sporozoite challenge [29,30]. Immune serum from
sporozoite-immunized humans can also block the invasion
of Pf sporozoites into hepatocytes [31]. In addition, the
RTS,S vaccine induces high titers of CS-protein-specific
Abs that correlate with protection against infectious chal-
lenge. The mechanism underlying Ab-mediated protection
could involve inhibition of hepatocyte invasion or opsoni-
zation of sporozoites for uptake by macrophages and DC.
Recent studies [32] have also shown that sporozoites
injected into the dermis of immunized mice are immobi-
lized and become degraded within hours. Moreover, mos-
quitoes introduce fewer sporozoites into immunized as
compared to non-immunized mice, presumably due to
the formation of Ag–Ab complexes in the proboscis [32].
Consequently, RTS,S-induced Abs probably also inhibit
sporozoite motility.
Because sporozoites invade hepatocytes soon after in-
jection, sufficiently high titers of sporozoite-specific Abs
must be present at the time of injection for Abs to confer
protection. This implies a need for sustained Ab production
by long-lived plasma cells (PC) (Figure 2). The activation of
these cells appears to involve Ags expressing both a repet-
itive epitope to mediate high B cell receptor cross-linking
and T cell epitopes to induce the activation of follicular T-
helper (TFH) cells [33]. Particular attenuated virus vac-
cines meet these criteria and can induce Ab responses that
persist for decades without apparent re-boosting [34,35].
Long-term storage of Ag–Ab–complement complexes on
follicular DC [36] could also be required.
For the RTS,S vaccine the majority of non-protected
volunteers make much weaker CS-protein-specific Ab
responses than protected volunteers. In addition, CS-pro-
tein-specific Ab titers fall substantially with time after the
3rd dose, even when accompanied by natural boosting [37].
Hence, mechanisms that sustain high Ab titers would
probably also improve long-term vaccine efficacy. In gen-
eral, higher primaryAb titers and longer intervals between
boosting tend to favor longer-lived Ab responses, and it
would therefore be worth evaluating at 0, 1, and 6 months
instead of in the standard 0, 1, and 2months immunization
schedule. There is also evidence [38] that high avidity Abs
are more protective than low-avidity Abs, thus methods to
increase Ab avidity would probably improve RTS,S-in-
duced protection.
CD4 T cell immunity
There is evidence that CD4 T cells also protect against the
pre-erythrocytic stages of malaria. CD4 T cells specific for a
Py CS-protein epitope can both eliminate infected hepato-
cytes in vitro and adoptively transfer protection in vivo
[39]. As mentioned, the RTS,S vaccine induces high titers
of CS-protein-specific IgG Abs, and this probably depends
on the activation of CS-protein-specific CD4 TFH cells.
RTS,S-primed CD4 T cells can also be recalled with CS-
protein peptides to produce IFN-g [27], a known inhibitor
of intracellular stages of the parasite [40]. Moreover, the
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frequency of the RTS,S-induced IFN-g+ CD4 T cells was
higher in protected than in non-protected volunteers [27].
Studies of other pathogens in both mice [41] and
humans [42] indicate that multifunctional CD4 T cells
simultaneously producing IL-2, IFN-g and TNF-a more
strongly associate with protection than bi- or mono-func-
tional CD4 T cells. This could be due to the capacity of IL-2
to promote lymphoproliferation and hence maintain the
lineage and the capacity of IFN-g and TNF-a to act syner-
gistically. In addition, the intensity of IFN-g secretion from
multifunctional cells appears to be greater than that of
terminal effector cells. Seder et al. [43] have proposed a
model in which CD4 T cells progressively gain and then
eventually lose effector function as they proceed along the
following linear differentiation pathway: IL-2+ TNF-a+
cells IL-2+ TNF-a+ IFN-g+ cells [TNF-a+ IFN-g+] or
[IL-2+ IFN-g+] cells IFN-g+-only terminal effector cells.
They propose that an ideal vaccine will be strong enough to
drive CD4 T cells to differentiate into IL-2+ TNF-a+ IFN-g+
triple producers (referred to as the ‘sweet spot’), but not so
strong as to further differentiate them into terminal effec-
tors.
The CD4 T cell lineage also includes regulatory T (Treg)
cells which are generally controlled by the transcription
factor FOXP3 (reviewed in [44]) and which limit excessive
inflammation and inhibit sterilizing immunity to patho-
gens. For example, Treg cells prevent effector T cells from
completely eliminating Leishmania parasites from the site
of infection, and the persistence of residual parasites con-
tributes to the maintenance of long-term immunity [45].
There are several reports that Treg cells control immune
responses to blood stage malaria [46,47] and, although
there is no direct evidence, they could also regulate
responses to the pre-erythrocytic stages. It is clear that
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Figure 2. Induction of humoral immunity. Region 1: a subunit vaccine – in this case the circumsporozoite (CS) protein coupled to a pathogen-associated molecular pattern
(PAMP) – is taken up into an endosome by an Ag-presenting cell (APC). The PAMP interacts with a pattern-recognition receptor (PRR), either on the cell surface or within the
endosome, and this stimulates maturation of the APC (Figure 3 legend). Following digestion of the protein within the endosome and binding of the resulting peptide
fragments to the binding-grooves of class II major histocompatibility molecules, recognition of CS-protein peptide plus class II molecule on the APC surface by an Ag-
specific CD4+ T cell induces upregulation of CXCR5 and differentiation of the CD4+ T cell into a follicular T-helper cell (TFH). B cell activation also occurs, causing some B cells
to differentiate into short-lived plasma cells (PC) and others to migrate to the interface between the T cell region and the B cell follicle. Region 2: further interaction of the B
cells with the TFH cells initiates the germinal center reaction. The B cells start to proliferate, form long-lived complexes with a network of follicular DC (FDC), and eventually
differentiate into memory B (BM) cells or into B-lymphocyte-induced maturation protein (Blimp-1) positive B cells and then into long-lived PC. Region 3: the PCs migrate to
the bone marrow where they reside in association with stromal cells and secrete IgG Ab for very long periods of time. Region 4: this CS-protein-specific Ab can immobilize
sporozoites immediately following injection by the mosquito and hence can confer protection against infection.
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future immunization strategies might have to consider
whether a vaccine activates Treg cells in addition to effector
and memory T cells and, if this is the case, identify a
method to counteract the effects of Treg cells such as the
coadministration of an immunomodulatory drug [46].
CD8 T cell immunity
Although Abs and CD4 T cells contribute to protection,
CD8 T cells appear to be the sine qua non effectors that
confer sterile immunity in some strains of attenuated
sporozoite-immunized mice. Thus, for example, depletion
of CD8+ cells from RAS-immunized BALB/c mice before
challenge abrogates protection. In addition, CD8 transgen-
ic T cells specific for Py CS protein can secrete IFN-g in
response to and protect mice against sporozoite challenge.
Recently it has been demonstrated that GAS immuniza-
tion of mice also activates CD8 T cells that are required for
protection [48] and which can effect contact-dependent
killing of Py-infected hepatocytes [49].
CD8 T cells specific for Pf CS protein have also been
found in the blood of both RAS-immunized volunteers and
naturally exposed subjects [21,50]. In addition, investiga-
tors working at the University of Oxford have explored the
use of vaccines encoding the pre-erythrocytic stage throm-
bospondin-related adhesion protein Ag (TRAP) fused to a
string of linked T- and B-cell epitopes (ME-TRAP), and
showed that priming humans with a construct of chimpan-
zee (Ch) adenovirus 63 encoding ME-TRAP (AdCh63–ME-
TRAP), followed by a boost with a modified vaccinia
Ankara (MVA) construct MVA–ME-TRAP, induced strong
CD8 g-interferon-secreting T cell responses and the asso-
ciated efficacy data has been submitted for publication
(Ewer et al., submitted, Adrian Hill, personal communica-
tion).
There is evidence that some sporozoites migrate from
the dermis to the draining lymph node where they activate
CS-protein-specific CD8 T cells [51]. These CD8 T cells
subsequently travel to the liver where they could contrib-
ute to pre-erythrocytic stage immunity. It is more likely,
however, that attenuated sporozoites also induce CD8 T
cells that are specific for the liver-stage Ags developing
only in infected hepatocytes.
Attenuated sporozoites activate CD8 T cells, whereas
native sporozoites do not, and this could be related to the
former causing infected hepatocytes to undergo apoptosis
[52,53]. The apoptotic cells are probably taken up by intra-
hepatic CD8+ DC for cross-presentation of liver-stage Ags
to CD8 T cells [54]. This mechanism, however, has been
called into question [55], in part because native sporo-
zoites can also induce sterile immunity in humans when
administered with chloroquine to prevent blood stage
infection [56], although there is the additional proviso
that immunity in this case could have been directed
primarily against very early blood stages that exit the
liver. Protection, in this case, appears to be mediated by
multi-functional effector memory T (TEM) cells, and chlo-
roquine could have potentiated the activation of these
cells [57].
In general, acute infection of humans or mice with a
pathogen causes CD8 T cells to undergo rapid expansion
to generate a large population of effector cells. Upon
pathogen clearance, the cells undergo rapid contraction
when most of the cells die by apoptosis. However, 5–10%
of the effector cells survive and form long-lived memory
CD8 T cells. The extent of contraction, and the mainte-
nance of memory cells, appear to depend on several gc
cytokines including IL-7, IL-15 and IL-21. Immunization
of mice with RAS or GAS results in the accumulation in
the liver of both CD44+ CD62L– CD122– CD8+ effector/
effector memory T(TE/EM) cells and CD44
+ CD62L+
CD122+ CD8+ central memory T (TCM) cells [58,59]. Sur-
prisingly, the CD8 TE/EM cells do not undergo contraction
after the last boost/immunization or after sporozoite
challenge, even after a prolonged period of time. It is
conceivable that the lack of contraction is due to chronic
Ag stimulation, and this would be consistent with RAS
immunization generating a persisting Ag depot. It is not
clear whether protection against sporozoite challenge
requires the protracted presence of CD8 TE cells that
could respond immediately to infection. If, by contrast,
protection depends on CD8 TCM cells that can only be
recruited from a draining lymph node, there could be
insufficient time for these cells to recognize new parasite
Ag, multiply to high numbers, and migrate to the liver to
kill the parasite. Conversely, if CD8 TCM cells are main-
tained in the liver, temporal constraints might not apply.
One of the key questions for the development of a malaria
subunit vaccine is, therefore, whether protection against
sporozoite challenge requires persisting CD8 TE cells or
CD8 TCM cells and, if the former, whether the mainte-
nance of these cells depends on a persisting depot of Ag. It
is worth noting that primaquine treatment to eliminate
persisting liver-stage Ag before the development of long-
lived memory cells abolished protection in both RAS [60]
and GAS [61]-immunized animals.
Valuable data regarding the role of central versus effec-
tor memory CD8 T cells have been provided by investiga-
tors at the University of Oxford. Volunteers were
immunized with ME-TRAP; DNA and fowlpox constructs
were used for priming, and anMVA construct provided the
boost. In some cases, vaccine-induced reduction in liver-
stage burden correlated more closely with long-term (cells
cultured for 9 d) than with short-term (cells cultured for
18 h) responses as measured by enzyme-linked immuno-
spot (ELISPOT) assay, indicating that TCM cells present at
the time of sporozoite challenge could make a greater
contribution to protection than TEM cells [62,63]. A princi-
pal hindrance to answering these questions in the RAS
model is our lack of knowledge of the Ags expressed by the
liver stage of the parasite. Consequently, extensive efforts
employing both genomics and proteomics are being direct-
ed to discovering relevant liver stage Ags [23–25]. For
example, 16 novel Pf proteins have been recently identified
which peripheral blood mononuclear cells (PBMC) from
RAS-immunized volunteers recognized more frequently
than ‘traditional’ Pf Ags such as the CS protein and
exported protein-1 (EXP-1) [64]. Moreover, two of these
16 Ags elicited higher responses from protected versus
non-protected volunteers.
Once the mechanisms that enable attenuated sporo-
zoites to induce sterile CD8 T-cell-mediated immunity
are understood, attempts could be made to trigger similar
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immune mechanisms by a subunit vaccine. The initiation
of the appropriate activation pathways will probably occur
in the lymph node draining the vaccination site. Figure 3
illustrates the cellular interactions that lead to the activa-
tion of short-lived effector CD8 T cells (SLECs), memory
potential effector CD8 T cells (MPECs) and memory CD8 T
cells, as well as the migration of these cells from the lymph
node to the liver to mediate their effector function.
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Figure 3. Induction of T cell mediated immunity. Region 1: a subunit vaccine – in this case a liver-stage antigen (Ag) coupled to a pathogen-associated molecular pattern
(PAMP) – is taken up into an endosome by an Ag-presenting cell (APC). The PAMP interacts with a pattern-recognition receptor (PRR), either on the cell surface or within the
endosome, and this stimulates the maturation of the APC. Region 2: Ag within early endosomes is degraded and binds to nascent class II molecules for transport to the cell
surface. Recognition of the peptide class II complex, followed by co-stimulation (Co St), induces the activation of Ag-specific CD4 T cells and these cells license the APC and
enable it to activate CD8 T cells. Region 3: some Ag is translocated out of the endosome into the cytoplasm where it is degraded into peptides by the proteosome. The
peptides are transported into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) where they are bound to nascent class I
molecules and then trimmed to size by the ER aminopeptidase (ERAP) enzymes. The peptide class I complexes are then transported to the cell surface. Region 4: the peptide
class I complexes are recognized by Ag-specific CD8+ T cells which undergo proliferation under the influence of costimulation and APC-derived IL-12. The proximal
daughter upregulates the T box expressed in T cells transcription factor (T-BET) and Blimp-1 and develops into a short-lived effector cell (SLEC) while the distal daughter
becomes a long-lived memory CD8 T (TM) cell. Region 5: during CD8 T cell expansion some effector cells do not down regulate CD127, and under the influence of IL-7
differentiate into memory potential effector cells (MPECS). Region 6: the sporozoite migrates through the Kupffer cell (KC) and several hepatocytes to lodge in a terminal
hepatocyte within a parasitophorous vacuole. The CD8 effector T cells leave the lymph node and migrate to the space of Disse or into the sinusoid of the liver. They
recognize parasite Ag plus class I on the surface of the infected hepatocyte and elaborate IFN-g and perforin/granzyme (P/G) to kill the parasite. Region 7: as a result of cell
traversal or of protein shedding, KC and other APC also process and present parasite Ags to activate CD4 and CD8 T cells in the sinusoid of the liver. These cells produce
TNF-a which can also act at a distance to kill the parasite. The cytokine milieu of the liver might also promote the activation of regulatory T cells (Treg), and these could
secrete IL-10 to suppress the activation of effector T cells.
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Key research questions
RTS,S vaccine trials have shown that both Abs and CD4 T
cells specific for the CS protein confer sterile immunity to
about 50% of malaria-naı¨ve volunteers and partial immu-
nity to children in endemic areas. RAS sporozoite vaccines
also confer sterile immunity and, in the mouse model, CD8
T cells specific for currently unidentified liver stage Ags
appear to be the keymediators of protection.Most recently,
data from a fowlpox prime and MVA boost regimen (using
the ME-TRAP antigen) suggest that T lymphocytes can
provide sterile immunity in humans in the absence of
significant antibody responses [65]. Hence, there appear
to be multiple immune responses that can be harnessed to
achieve pre-erythrocytic stage immunity. Key outstanding
questions regarding the induction and maintenance of
protective immunity to pre-erythrocytic stage antigens
are listed in Table 1.
Conclusions and future directions
Long-termmaintenance of high titers of sporozoite surface-
Ag-specific Abs will be an important component of the
protective immunity induced by vaccines, probably
depending upon the generation of long-lived PCs. In gen-
eral, stronger primary Ab responses correlate with stron-
ger and more long-lived booster responses, and therefore
adjuvants and vaccine platforms that favor strong primary
responses could contribute to the longevity of the Ab
response. Longer times between prime and boost immu-
nizations also favor long-lived Ab production [66]. Enhanc-
ing the expression of the transcription repressor Blimp-1,
which promotes the differentiation of B cells into long-lived
PC [67], might be achieved by activating IL-21-secreting
TFH cells, and this could also favor durable Ab production.
An effective malaria vaccine should also induce strong
and long-lasting pre-erythrocytic stage T cell immunity.
The identification of the most protective pre-erythrocytic
stage Ags is a primary objective. It will be necessary to
establish whether intra-hepatic TE cells or TCM cells are
the main contributors to protracted T cell immunity and to
confirm whether the preservation of TE cells requires a
persistent Ag depot. It follows that adjuvants that create
an Ag depot or a recombinant virus generating persistent
latent infection [68] might help to maintain multi-func-
tional TEM cells in the peripheral tissue. The highly suc-
cessful yellow fever vaccine targets four different TLRs
located on distinct sub-populations of DCs, each with its
own unique booster-effect on the immune system [69].
Hence, a combination of malaria Ags with multiple com-
ponent adjuvants that target different TLRs could lead to a
TH1/TH2 balance favoring long-lived Ab production and
long-lived T cell memory. Other adjuvants such as Iscoma-
trix (cage-like structures consisting of saponin, phospho-
lipid and cholesterol) could also be considered, to enhance
Ab as well as CD4 and CD8 T cell responses in humans
[70].
Alternatively, vaccine platforms with intrinsic immu-
nostimulatory properties could be employed to achieve a
similar broad activation of humoral and cellular immunity.
Combining RTS,S with a viral vector expressing either CS
protein or other appropriate sporozoite or liver-stage Ags
in a prime and boost regimen could induce both strong Ab
and CD4 and CD8 T cell responses leading to more durable
protection [71]. In support, a study in macaques demon-
strated that two doses of RTS,S following an adenovirus 35
CS-protein priming immunization retained the RTS,S-in-
duced Ab response while promoting a markedly higher
CD4 T-cell response that remained elevated for about 2
months [72].
Finally, a subunit vaccine will need to be immunogenic
in humans, who generally exhibit a high degree of genetic
Table 1. Outstanding issues in malaria vaccine development
Ab-mediated immunity Refs
Identify mechanisms that maintain high titers of CS-protein-specific Abs for a prolonged period of time [33–36,66,67,69]
Determine the role of Abs specific for non-CS-protein sporozoite Ags [16,73,74]
Establish the contribution to protection of Ab responses targeting malaria proteins expressed on the
surface of infected hepatocytes
[75]
Identify mechanisms to induce production of high-avidity Abs [38]
T cell-mediated immunity
Identify the key sporozoite and liver-stage Ags that stimulate protective CD4 and CD8 T cell-mediated immunity [23–25,64]
Determine if there is a requirement for persisting CD4/CD8 TE cells or CD4/CD8 TCM cells (or both)
for long-term protection
[50,51,54,58,59,61,76]
Establish whether there is a need for chronic stimulation from a persisting Ag depot to maintain long-lived
intra-hepatic CD4/CD8 TE cells
[36,49,60,61]
Characterize the relative contribution of multi-functional CD4/CD8 T cells versus unifunctional CD4/CD8
T cells in conferring protection
[27,41,42]
Identify the primary site (liver or lymph node draining the liver) of pre-erythrocytic stage Ag-specific
CD4/CD8 T cell activation
[15,51,54,69]
Determine whether CD4/CD8 T cells induced by subcutaneous or intramuscular immunization with
subunit vaccines migrate to the liver
[51]
Identify a cross-presentation pathway that can be targeted by exogenous Ag to activate CD8 T cells [54,77,78]
Establish whether CD4 TFH cells promote the differentiation of pre-erythrocytic stage-specific BM
cells and long-lived PC cells
[33]
Determine whether regulatory T cells inhibit responses to pre-erythrocytic stage Ags [7,44–47,56]
Elucidate to what extent host and parasite genetic diversity affect CD4/CD8 T-cell responses to
pre-erythrocytic stage Ags
[19,21,79]
Abbreviations: CS, circumsporozoite; Ab, antibody; Ag, antigen; TE, effector T cell; TCM, central memory T cell; TFH, follicular helper T cell; BM, memory B cell; PC, plasma cell.
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diversity. One approach to overcoming genetic restriction
would be to employ a subunit vaccine containing epitopes
from multiple antigens, including universal epitopes that
bind to multiple HLA types. In addition, it might be
possible to choose epitopes that are restricted by HLA
supertypes.
In summary, a successful pre-erythrocytic stagemalaria
vaccine will have to induce a durable antibody response
against the sporozoite and a protracted CD4 and CD8
protective T cell response against the liver stages of the
parasite. These goals should be achievable using the ap-
propriate immunization regimens in conjunctionwith new-
ly developed adjuvants and vaccine delivery vehicles. A
malaria vaccine will also have to address human genetic
diversity, possibly by including universal T cell epitopes, as
well as the genetic diversity in the parasite itself. Clearly,
we are moving closer to the development of a successful
malaria vaccine, but much work remains to be done.
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